1. Home
  2. BIOX vs OTLK Comparison

BIOX vs OTLK Comparison

Compare BIOX & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioceres Crop Solutions Corp.

BIOX

Bioceres Crop Solutions Corp.

HOLD

Current Price

$0.47

Market Cap

35.6M

Sector

Industrials

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.23

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIOX
OTLK
Founded
2001
2010
Country
Argentina
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.6M
29.2M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
BIOX
OTLK
Price
$0.47
$0.23
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
$4.33
$2.50
AVG Volume (30 Days)
308.0K
4.4M
Earning Date
05-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.91
EPS
N/A
N/A
Revenue
N/A
$8,146,123.00
Revenue This Year
N/A
$1,430.98
Revenue Next Year
$37.82
$173.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.16
52 Week High
$5.18
$3.39

Technical Indicators

Market Signals
Indicator
BIOX
OTLK
Relative Strength Index (RSI) 43.50 43.97
Support Level $0.42 $0.17
Resistance Level $0.68 $0.29
Average True Range (ATR) 0.05 0.02
MACD -0.00 -0.00
Stochastic Oscillator 8.75 27.43

Price Performance

Historical Comparison
BIOX
OTLK

About BIOX Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: